GleamWall
中文EN

MNKD MANNKIND CORP

Pharmaceutical Preparations · Nasdaq · SEC CIK 899460 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY31.7%
TTM net income YoY-356.0%
TTM EPS YoY-340.0%
Revenue 3-yr CAGR32.8%
Net income 3-yr CAGR—

Margins

Gross margin88.6%
Operating margin-2.9%
Net margin-18.1%
FCF margin-19.0%
EBITDA margin1.1%

Returns

ROE—
ROA-12.3%
ROIC (approx.)-10.5%
Asset turnover0.68x

Leverage & solvency

Liabilities / assets105.2%
Debt / equity—
Current ratio2.22x
Interest coverage-0.34x

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-1.4%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$348.97M$285.50M
Cost of revenue$26.80M$17.43M
Gross profit$322.17M$268.07M
R&D expense$66.35M$45.89M
SG&A expense$144.13M$94.33M
Operating income$38.80M$72.59M
Interest expense$13.83M$11.98M
Pretax income$1.41M$30.52M
Income tax-$4.46M$2.93M
Net income$5.86M$27.59M
EBITDA$51.09M$79.96M
EPS (basic)0.020.10
EPS (diluted)0.020.10
Weighted avg. shares (diluted)314.11M283.84M
Balance sheet
Cash & equivalents$74.88M$46.34M
Short-term investments$96.46M$150.92M
Receivables$38.37M$11.80M
Inventory$35.31M$27.89M
Current assets$291.58M$268.31M
PP&E, net$82.42M$85.36M
Goodwill$67.59M$1.93M
Intangibles$5.07M$5.26M
Total assets$792.18M$393.84M
Current liabilities$171.03M$81.84M
Long-term debt$354.64M$36.05M
Total debt$354.64M$36.05M
Total liabilities$843.20M$472.66M
Shareholders' equity-$51.02M-$78.82M
Net debt$279.76M-$10.29M
Shares outstanding307.83M302.96M
Cash flow statement
Operating cash flow$18.25M$42.51M
Capital expenditure$4.57M$9.69M
Free cash flow$13.69M$32.82M
Investing cash flow-$304.80M-$96.65M
Financing cash flow$315.10M-$137.27M
Depreciation & amortization$12.28M$7.37M
Stock-based compensation$24.20M$21.36M

Free plan shows the latest 2 periods; Pro shows all 33 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.